273 related articles for article (PubMed ID: 11279634)
1. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
van Der Auwera P; Platzer E; Xu ZX; Schulz R; Feugeas O; Capdeville R; Edwards DJ
Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
[TBL] [Abstract][Full Text] [Related]
2. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR
Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
[TBL] [Abstract][Full Text] [Related]
6. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective.
Faulkner LB; Tucci F; Tamburini A; Tintori V; Lippi AA; Bambi F; Malentacca F; Azzari C; Gelli AM; Genovese F; Bernini G
Bone Marrow Transplant; 1998 Jun; 21(11):1091-5. PubMed ID: 9645570
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.
Hernández-Bernal F; García-García I; González-Delgado CA; Valenzuela-Silva C; Soto-Hernández R; Ducongé J; Cervantes-Llano M; Blanco-Garcés E; Rodríguez V; García-Vega Y; Bello-Rivero I; Olivera-Ruano L; López-Saura P
Biopharm Drug Dispos; 2005 May; 26(4):151-9. PubMed ID: 15799006
[TBL] [Abstract][Full Text] [Related]
8. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
Kroschinsky F; Hölig K; Poppe-Thiede K; Zimmer K; Ordemann R; Blechschmidt M; Oelschlaegel U; Bornhauser M; Rall G; Rutt C; Ehninger G
Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
[TBL] [Abstract][Full Text] [Related]
9. Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.
Krzyzanski W; Wiczling P; Lowe P; Pigeolet E; Fink M; Berghout A; Balser S
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):101S-112S. PubMed ID: 20881223
[TBL] [Abstract][Full Text] [Related]
10. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
11. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
12. Repeated hematopoietic stem and progenitor cell mobilization without depletion of the bone marrow stem and progenitor cell pool in mice after repeated administration of recombinant murine G-CSF.
de Kruijf EJ; van Pel M; Hagoort H; Kruysdijk D; Molineux G; Willemze R; Fibbe WE
Hum Immunol; 2007 May; 68(5):368-74. PubMed ID: 17462504
[TBL] [Abstract][Full Text] [Related]
13. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
[TBL] [Abstract][Full Text] [Related]
15. Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol.
Eliason JF; Greway A; Tare N; Inoue T; Bowen S; Dar M; Yamasaki M; Okabe M; Horii I
Stem Cells; 2000; 18(1):40-5. PubMed ID: 10661570
[TBL] [Abstract][Full Text] [Related]
16. [Mobilization of autologous peripheral blood stem cells with etoposide and recombinant human granulocyte colony stimulating factor in malignant tumor patients].
Shi YK; He XH; Han XH; Yang JL; Liu P; Zhang CG; Ai B
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):360-3. PubMed ID: 15312348
[TBL] [Abstract][Full Text] [Related]
17. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
18. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
[TBL] [Abstract][Full Text] [Related]
19. Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers.
Schwinger W; Mache C; Urban C; Beaufort F; Töglhofer W
Bone Marrow Transplant; 1993 Jun; 11(6):489-92. PubMed ID: 8334430
[TBL] [Abstract][Full Text] [Related]
20. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
